SCHEMBL19296181

SCHEMBL19296181

COc1ccc(COC(=O)[C@@H](N)Cc2ccccc2F)c(OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP10 Q53GL7 2/20 0.50
PARP15 Q460N3 1/20 0.50
PARP14 Q460N5 1/20 0.45
ALDH1A1 P00352 3/20 0.44
LMNA P02545 2/20 0.44
PTPN1 P18031 1/20 0.43
KDM4E B2RXH2 1/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
PRKCZ Q05513 1/20 0.40
PKM P14618 3/20 0.40
RAB9A P51151 3/20 0.40
CTSD P07339 1/20 0.40
MAPK1 P28482 1/20 0.40
TACR1 P25103 2/20 0.40
NPC1 O15118 2/20 0.40
ALOX5 P09917 1/20 0.40
GAA P10253 1/20 0.40
HPGD P15428 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20597773 1.00 PARP10 (0.50) PARP10PARP15PARP14ALDH1A1LMNA
SCHEMBL3219669 0.85 CAPN1 (0.49) ALDH1A1KDM4ETSHRMEN1KMT2A
SCHEMBL238387 0.85 CAPN1 (0.49) ALDH1A1KDM4ETSHRMEN1KMT2A
SCHEMBL17542446 0.81 TACR1 (0.64) LMNAKDM4ETSHRMEN1KMT2A
SCHEMBL17542447 0.81 TACR1 (0.64) LMNAKDM4ETSHRMEN1KMT2A
SCHEMBL30006546 0.80 ALDH1A1 (0.52) PARP10PARP15PARP14ALDH1A1LMNA
SCHEMBL28622709 0.78 ALDH1A1 (0.49) ALDH1A1KDM4ETSHRMEN1KMT2A
SCHEMBL23201898 0.78 APLNR (0.51) ALDH1A1MEN1KMT2ATP53
SCHEMBL23201900 0.78 APLNR (0.51) ALDH1A1MEN1KMT2ATP53
SCHEMBL28154279 0.78 HTR2A (0.48) ALDH1A1MEN1KMT2ATP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109963835-B Preparation method of neotoxin and intermediate thereof 江苏恒瑞医药股份有限公司 2022-10-21 CN disclosed
CN-107531680-B Preparation method of toxin and intermediate thereof 江苏恒瑞医药股份有限公司 2020-09-11 CN disclosed
CN-109963835-A A kind of preparation method of new toxin and its intermediate 江苏恒瑞医药股份有限公司 2019-07-02 CN disclosed
US-20190055223-A1 TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2019-02-21 US disclosed
US-20190055223-A1 TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF SHANGHAI HENGRUI PHARMACEUTICAL CO., LTD. (CN) 2019-02-21 US disclosed
EP-3421463-A1 NEW TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF Jiangsu Hengrui Medicine Co., Ltd. (CN) 2019-01-02 EP disclosed
CN-107531680-A A kind of preparation method of new toxin and its intermediate 江苏恒瑞医药股份有限公司 2018-01-02 CN disclosed
WO-2017144015-A1 NEW TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF 江苏恒瑞医药股份有限公司 2017-08-31 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190055223-A1 TOXIN AND METHOD FOR PREPARING INTERMEDIATE THEREOF VIP, HABP2, FURIN PARP10 2959/4885PARP15 2400/4885PARP14 2349/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.